SK37997A3 - Compositions and methods for treating mast-cell inflammatory condition - Google Patents

Compositions and methods for treating mast-cell inflammatory condition Download PDF

Info

Publication number: SK37997A3
Authority: SK; Slovakia
Prior art keywords: cis; compound; bis; piperazinecarboxylate; cyclooctylene
Prior art date: 1994-09-23

Application number

SK379-97A

Other languages

English (en)

Slovak (sk)

Inventor

Ken D Rice

Jeffrey M Dener

Anthony R Gangloff

Elaine Yee-Lin Kuo

Original Assignee

Arris Pharm Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-23

Filing date

1995-09-14

Publication date

1998-12-02

1995-09-14 Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp

1998-12-02 Publication of SK37997A3 publication Critical patent/SK37997A3/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 76
238000000034 method Methods 0.000 title claims abstract description 58
210000003630 histaminocyte Anatomy 0.000 title abstract description 19
230000004968 inflammatory condition Effects 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 179
238000011282 treatment Methods 0.000 claims abstract description 38
208000006673 asthma Diseases 0.000 claims abstract description 32
208000027866 inflammatory disease Diseases 0.000 claims abstract description 26
230000001404 mediated effect Effects 0.000 claims abstract description 22
238000002360 preparation method Methods 0.000 claims abstract description 13
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 9
206010010741 Conjunctivitis Diseases 0.000 claims abstract description 7
206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 7
201000010105 allergic rhinitis Diseases 0.000 claims abstract description 7
210000002345 respiratory system Anatomy 0.000 claims abstract description 7
230000000699 topical effect Effects 0.000 claims abstract description 4
-1 trans-4-aminomethylcyclohexylmethylcarbamoyl Chemical group 0.000 claims description 125
125000002947 alkylene group Chemical group 0.000 claims description 85
125000000217 alkyl group Chemical group 0.000 claims description 47
150000003839 salts Chemical class 0.000 claims description 39
239000000443 aerosol Substances 0.000 claims description 29
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
KNOCWIRLLNOGLX-UHFFFAOYSA-N C1=CC(=CC=C1CNC(=O)CNC(=O)O)N=C(N)N Chemical compound C1=CC(=CC=C1CNC(=O)CNC(=O)O)N=C(N)N KNOCWIRLLNOGLX-UHFFFAOYSA-N 0.000 claims description 17
239000001257 hydrogen Substances 0.000 claims description 17
229910052739 hydrogen Inorganic materials 0.000 claims description 17
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 14
125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 13
KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 claims description 13
238000009472 formulation Methods 0.000 claims description 12
150000002431 hydrogen Chemical class 0.000 claims description 12
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 11
239000003937 drug carrier Substances 0.000 claims description 11
ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 11
125000005842 heteroatom Chemical group 0.000 claims description 11
125000005407 trans-1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])[C@]([H])([*:2])C([H])([H])C([H])([H])[C@@]1([H])[*:1] 0.000 claims description 10
241000124008 Mammalia Species 0.000 claims description 9
125000004978 cyclooctylene group Chemical group 0.000 claims description 9
239000000808 adrenergic beta-agonist Substances 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
239000000651 prodrug Substances 0.000 claims description 8
229940002612 prodrug Drugs 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 7
230000009385 viral infection Effects 0.000 claims description 7
125000004956 cyclohexylene group Chemical group 0.000 claims description 6
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 6
201000004624 Dermatitis Diseases 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
208000036142 Viral infection Diseases 0.000 claims description 5
150000007942 carboxylates Chemical class 0.000 claims description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
239000000843 powder Substances 0.000 claims description 5
ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 claims description 4
AFFLGGQVNFXPEV-UHFFFAOYSA-N 1-decene Chemical group CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 claims description 4
150000001409 amidines Chemical class 0.000 claims description 4
HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 claims description 4
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
125000004979 cyclopentylene group Chemical group 0.000 claims description 4
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 3
229960001022 fenoterol Drugs 0.000 claims description 3
LSLYOANBFKQKPT-UHFFFAOYSA-N fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 claims description 3
229960002848 formoterol Drugs 0.000 claims description 3
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 3
229960000195 terbutaline Drugs 0.000 claims description 3
GMTVPAVDCNDLQF-UHFFFAOYSA-N 12-[4-[[4-(diaminomethylideneamino)phenyl]methylcarbamoyl]piperazine-1-carbonyl]oxydodecyl 4-[[4-(diaminomethylideneamino)phenyl]methylcarbamoyl]piperazine-1-carboxylate Chemical compound N(C(=N)N)C1=CC=C(CNC(=O)N2CCN(CC2)C(=O)OCCCCCCCCCCCCOC(=O)N2CCN(CC2)C(NCC2=CC=C(C=C2)NC(=N)N)=O)C=C1 GMTVPAVDCNDLQF-UHFFFAOYSA-N 0.000 claims description 2
CZQCTKVWGSVIOM-UHFFFAOYSA-N NC(NC1=CC=C(CNC(N(CC2)CCN2C(OCCCCCC=CCCCOC(N(CC2)CCN2C(NCC(C=C2)=CC=C2NC(N)=N)=O)=O)=O)=O)C=C1)=N Chemical compound NC(NC1=CC=C(CNC(N(CC2)CCN2C(OCCCCCC=CCCCOC(N(CC2)CCN2C(NCC(C=C2)=CC=C2NC(N)=N)=O)=O)=O)=O)C=C1)=N CZQCTKVWGSVIOM-UHFFFAOYSA-N 0.000 claims description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 2
125000006639 cyclohexyl carbonyl group Chemical group 0.000 claims description 2
229960002052 salbutamol Drugs 0.000 claims description 2
238000011200 topical administration Methods 0.000 claims description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
GNMCGMFNBARSIY-UHFFFAOYSA-N 1,2,3,4,4a,4b,5,6,7,8,8a,9,10,10a-tetradecahydrophenanthrene Chemical compound C1CCCC2C3CCCCC3CCC21 GNMCGMFNBARSIY-UHFFFAOYSA-N 0.000 claims 1
DBCJCAUXOLQIFH-UHFFFAOYSA-N NC(=N)Nc1ccc(CNC(=O)N2CCN(CC2)C(=O)OC2CCCCCCC2)cc1 Chemical compound NC(=N)Nc1ccc(CNC(=O)N2CCN(CC2)C(=O)OC2CCCCCCC2)cc1 DBCJCAUXOLQIFH-UHFFFAOYSA-N 0.000 claims 1
LDCLSJOJZDSYAD-UHFFFAOYSA-N NCCC1=CC=C(C(=O)C2N(CCNC2)C=O)C=C1 Chemical compound NCCC1=CC=C(C(=O)C2N(CCNC2)C=O)C=C1 LDCLSJOJZDSYAD-UHFFFAOYSA-N 0.000 claims 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
239000012049 topical pharmaceutical composition Substances 0.000 claims 1
108060005989 Tryptase Proteins 0.000 abstract description 33
230000002265 prevention Effects 0.000 abstract description 7
208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 2
230000003389 potentiating effect Effects 0.000 abstract description 2
229940124639 Selective inhibitor Drugs 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
239000000243 solution Substances 0.000 description 61
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 54
238000005160 1H NMR spectroscopy Methods 0.000 description 41
239000007787 solid Substances 0.000 description 40
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
102000001400 Tryptase Human genes 0.000 description 32
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
125000003118 aryl group Chemical group 0.000 description 29
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
229940126214 compound 3 Drugs 0.000 description 26
125000003545 alkoxy group Chemical group 0.000 description 24
125000004414 alkyl thio group Chemical group 0.000 description 21
239000000427 antigen Substances 0.000 description 21
102000036639 antigens Human genes 0.000 description 21
108091007433 antigens Proteins 0.000 description 21
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
241001465754 Metazoa Species 0.000 description 18
UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 18
241001494479 Pecora Species 0.000 description 17
230000004044 response Effects 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 16
238000001914 filtration Methods 0.000 description 16
239000000725 suspension Substances 0.000 description 16
125000002252 acyl group Chemical group 0.000 description 15
239000000126 substance Substances 0.000 description 15
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
239000012071 phase Substances 0.000 description 14
125000003107 substituted aryl group Chemical group 0.000 description 14
239000007788 liquid Substances 0.000 description 13
238000000746 purification Methods 0.000 description 13
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
239000007864 aqueous solution Substances 0.000 description 12
125000000547 substituted alkyl group Chemical group 0.000 description 11
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
201000010099 disease Diseases 0.000 description 10
125000000524 functional group Chemical group 0.000 description 10
239000012074 organic phase Substances 0.000 description 10
150000003254 radicals Chemical class 0.000 description 10
229920006395 saturated elastomer Polymers 0.000 description 10
125000005346 substituted cycloalkyl group Chemical group 0.000 description 10
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
206010061218 Inflammation Diseases 0.000 description 8
125000004423 acyloxy group Chemical group 0.000 description 8
125000004104 aryloxy group Chemical group 0.000 description 8
229940125782 compound 2 Drugs 0.000 description 8
230000000694 effects Effects 0.000 description 8
229910052736 halogen Inorganic materials 0.000 description 8
150000002367 halogens Chemical class 0.000 description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
230000004054 inflammatory process Effects 0.000 description 8
239000002244 precipitate Substances 0.000 description 8
239000007858 starting material Substances 0.000 description 8
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 8
125000003396 thiol group Chemical class [H]S* 0.000 description 8
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 7
230000036428 airway hyperreactivity Effects 0.000 description 7
125000004432 carbon atom Chemical group C* 0.000 description 7
238000001035 drying Methods 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
239000000463 material Substances 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
125000006239 protecting group Chemical group 0.000 description 7
SBJKLBMVVHKFNQ-UHFFFAOYSA-N 2-(methoxycarbonylamino)acetic acid Chemical compound COC(=O)NCC(O)=O SBJKLBMVVHKFNQ-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
125000005110 aryl thio group Chemical group 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000012230 colorless oil Substances 0.000 description 6
239000012456 homogeneous solution Substances 0.000 description 6
108700025647 major vault Proteins 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
238000002953 preparative HPLC Methods 0.000 description 6
230000002441 reversible effect Effects 0.000 description 6
239000011734 sodium Substances 0.000 description 6
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
DTMJPALEWBKCAH-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)carbamic acid Chemical compound CCOC(=O)CNC(O)=O DTMJPALEWBKCAH-UHFFFAOYSA-N 0.000 description 5
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 5
239000013566 allergen Substances 0.000 description 5
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 5
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
208000023819 chronic asthma Diseases 0.000 description 5
BDNXUVOJBGHQFD-UHFFFAOYSA-N cyclooctane-1,5-diol Chemical compound OC1CCCC(O)CCC1 BDNXUVOJBGHQFD-UHFFFAOYSA-N 0.000 description 5
150000004985 diamines Chemical class 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
230000035874 hyperreactivity Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
239000000543 intermediate Substances 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
206010006482 Bronchospasm Diseases 0.000 description 4
208000008469 Peptic Ulcer Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
241000700605 Viruses Species 0.000 description 4
239000002253 acid Substances 0.000 description 4
208000026935 allergic disease Diseases 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
238000003556 assay Methods 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
208000010668 atopic eczema Diseases 0.000 description 4
239000002585 base Substances 0.000 description 4
230000007885 bronchoconstriction Effects 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
229940125904 compound 1 Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000003818 flash chromatography Methods 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
125000006588 heterocycloalkylene group Chemical group 0.000 description 4
230000006872 improvement Effects 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
208000017520 skin disease Diseases 0.000 description 4
NYXOBVVHJZENCO-UHFFFAOYSA-N tert-butyl n-[[4-(aminomethyl)cyclohexyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCC(CN)CC1 NYXOBVVHJZENCO-UHFFFAOYSA-N 0.000 description 4
CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 4
238000012360 testing method Methods 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
ZCQNPIDOULBSGN-UHFFFAOYSA-N 1-tert-butyl-1-[[4-(diaminomethylideneamino)phenyl]methyl]urea Chemical compound CC(C)(C)N(C(N)=O)CC1=CC=C(NC(N)=N)C=C1 ZCQNPIDOULBSGN-UHFFFAOYSA-N 0.000 description 3
LSJDCROQPZSAIP-UHFFFAOYSA-N 2-[4-(aminomethyl)phenyl]guanidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.NCC1=CC=C(N=C(N)N)C=C1 LSJDCROQPZSAIP-UHFFFAOYSA-N 0.000 description 3
BFWYZZPDZZGSLJ-UHFFFAOYSA-N 4-(aminomethyl)aniline Chemical compound NCC1=CC=C(N)C=C1 BFWYZZPDZZGSLJ-UHFFFAOYSA-N 0.000 description 3
206010002198 Anaphylactic reaction Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
241000725643 Respiratory syncytial virus Species 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229940122598 Tryptase inhibitor Drugs 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000008369 airway response Effects 0.000 description 3
230000036783 anaphylactic response Effects 0.000 description 3
208000003455 anaphylaxis Diseases 0.000 description 3
230000001088 anti-asthma Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000003123 bronchiole Anatomy 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
229960001334 corticosteroids Drugs 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
238000010494 dissociation reaction Methods 0.000 description 3
230000005593 dissociations Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000000605 extraction Methods 0.000 description 3
230000036541 health Effects 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000003463 hyperproliferative effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
238000002329 infrared spectrum Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
238000001819 mass spectrum Methods 0.000 description 3
LOFFMPAQJVAOOT-UHFFFAOYSA-N n-[[4-(diaminomethylideneamino)phenyl]methyl]piperazine-1-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.C1=CC(N=C(N)N)=CC=C1CNC(=O)N1CCNCC1 LOFFMPAQJVAOOT-UHFFFAOYSA-N 0.000 description 3
230000020477 pH reduction Effects 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
238000004007 reversed phase HPLC Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
YWAXHBRWHMJJOC-UHFFFAOYSA-N tert-butyl n-[4-(aminomethyl)phenyl]carbamate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)NC1=CC=C(CN)C=C1 YWAXHBRWHMJJOC-UHFFFAOYSA-N 0.000 description 3
KSXPGASLEFGROT-UHFFFAOYSA-N tert-butyl n-[[4-(hydroxymethyl)cyclohexyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCC(CO)CC1 KSXPGASLEFGROT-UHFFFAOYSA-N 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
239000002750 tryptase inhibitor Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
QYYZXEPEVBXNNA-QGZVFWFLSA-N (1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1[C@H](C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)O QYYZXEPEVBXNNA-QGZVFWFLSA-N 0.000 description 2
ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 2
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
WZBZWJITAGRGEK-UHFFFAOYSA-N 1-[(4-aminophenyl)methyl]-3-tert-butylurea;hydrochloride Chemical compound Cl.CC(C)(C)NC(=O)NCC1=CC=C(N)C=C1 WZBZWJITAGRGEK-UHFFFAOYSA-N 0.000 description 2
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
208000000884 Airway Obstruction Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010003645 Atopy Diseases 0.000 description 2
238000012935 Averaging Methods 0.000 description 2
BKRFIPGFROVKFR-UHFFFAOYSA-N CC(OC(=O)C)OC(=O)NC(=NC(=O)OC(C)OC(=O)C)N(C1=CC=C(C=C1)CNC(=O)N2CCN(CC2)C(=O)O)C(=O)OC(C)OC(=O)C Chemical compound CC(OC(=O)C)OC(=O)NC(=NC(=O)OC(C)OC(=O)C)N(C1=CC=C(C=C1)CNC(=O)N2CCN(CC2)C(=O)O)C(=O)OC(C)OC(=O)C BKRFIPGFROVKFR-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000700198 Cavia Species 0.000 description 2
RKXAGLQDXWJBSC-KMMPGQJCSA-N Cl.NC[C@H]1CC[C@H](CO)CC1 Chemical compound Cl.NC[C@H]1CC[C@H](CO)CC1 RKXAGLQDXWJBSC-KMMPGQJCSA-N 0.000 description 2
229940126657 Compound 17 Drugs 0.000 description 2
229940126639 Compound 33 Drugs 0.000 description 2
229940127007 Compound 39 Drugs 0.000 description 2
229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
206010012438 Dermatitis atopic Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
239000005977 Ethylene Substances 0.000 description 2
RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000009438 IgE Receptors Human genes 0.000 description 2
108010073816 IgE Receptors Proteins 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
208000007920 Neurogenic Inflammation Diseases 0.000 description 2
108090000189 Neuropeptides Proteins 0.000 description 2
235000019502 Orange oil Nutrition 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical group NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
208000024780 Urticaria Diseases 0.000 description 2
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
MPMRGQWPCGLCDV-UHFFFAOYSA-N [2-[(4-aminophenyl)methylamino]-2-oxoethyl]carbamic acid Chemical compound C1=CC(=CC=C1CNC(=O)CNC(=O)O)N MPMRGQWPCGLCDV-UHFFFAOYSA-N 0.000 description 2
SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
239000000464 adrenergic agent Substances 0.000 description 2
150000004703 alkoxides Chemical class 0.000 description 2
230000002009 allergenic effect Effects 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
150000003862 amino acid derivatives Chemical class 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
201000008937 atopic dermatitis Diseases 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
229960004484 carbachol Drugs 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 2
229940125773 compound 10 Drugs 0.000 description 2
229940125797 compound 12 Drugs 0.000 description 2
229940126543 compound 14 Drugs 0.000 description 2
229940125758 compound 15 Drugs 0.000 description 2
229940126142 compound 16 Drugs 0.000 description 2
229940125810 compound 20 Drugs 0.000 description 2
229940126086 compound 21 Drugs 0.000 description 2
229940126208 compound 22 Drugs 0.000 description 2
229940125833 compound 23 Drugs 0.000 description 2
229940125961 compound 24 Drugs 0.000 description 2
229940125846 compound 25 Drugs 0.000 description 2
229940125851 compound 27 Drugs 0.000 description 2
229940127204 compound 29 Drugs 0.000 description 2
229940125877 compound 31 Drugs 0.000 description 2
229940125807 compound 37 Drugs 0.000 description 2
229940127573 compound 38 Drugs 0.000 description 2
229940125844 compound 46 Drugs 0.000 description 2
229940127271 compound 49 Drugs 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
229940126545 compound 53 Drugs 0.000 description 2
OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
239000012043 crude product Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
229940045803 cuprous chloride Drugs 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
238000010908 decantation Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000001952 enzyme assay Methods 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
DUVOZUPPHBRJJO-UHFFFAOYSA-N ethyl 2-isocyanatoacetate Chemical compound CCOC(=O)CN=C=O DUVOZUPPHBRJJO-UHFFFAOYSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
150000004679 hydroxides Chemical class 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000002262 irrigation Effects 0.000 description 2
238000003973 irrigation Methods 0.000 description 2
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
239000010410 layer Substances 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
239000010502 orange oil Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
125000003367 polycyclic group Chemical group 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
235000019833 protease Nutrition 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
NCIQNWYJLAAFAH-UHFFFAOYSA-N tert-butyl 4-carbonochloridoylpiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C(Cl)=O)CC1 NCIQNWYJLAAFAH-UHFFFAOYSA-N 0.000 description 2
LZPYIMUXLDFQMM-UHFFFAOYSA-N tert-butyl n-[4-(isocyanatomethyl)phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(CN=C=O)C=C1 LZPYIMUXLDFQMM-UHFFFAOYSA-N 0.000 description 2
ALGJWXWBQMFOPX-UHFFFAOYSA-N tert-butyl n-[[4-(diaminomethylideneamino)phenyl]methyl]carbamate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)NCC1=CC=C(NC(N)=N)C=C1 ALGJWXWBQMFOPX-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000008719 thickening Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000000844 transformation Methods 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 1
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 description 1
DZVUUJGUZBCOCH-UHFFFAOYSA-N 1-[(4-aminophenyl)methyl]-3-tert-butylurea Chemical compound CC(C)(C)NC(=O)NCC1=CC=C(N)C=C1 DZVUUJGUZBCOCH-UHFFFAOYSA-N 0.000 description 1
PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 1
WWIKWOJUJQCHIZ-UHFFFAOYSA-N 1-methyl-9h-xanthene Chemical class O1C2=CC=CC=C2CC2=C1C=CC=C2C WWIKWOJUJQCHIZ-UHFFFAOYSA-N 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N 1-nonene Chemical group CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
MOKSHZWZRKXXAO-UHFFFAOYSA-N 2-[4-(aminomethyl)phenyl]guanidine Chemical compound NCC1=CC=C(NC(N)=N)C=C1 MOKSHZWZRKXXAO-UHFFFAOYSA-N 0.000 description 1
VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
DAKJXSWSZIQSTL-UHFFFAOYSA-N 2-phenylguanidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.NC(N)=NC1=CC=CC=C1 DAKJXSWSZIQSTL-UHFFFAOYSA-N 0.000 description 1
ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 1
PNIHOTDSIJXUMR-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonyl]piperazine-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCN(C(O)=O)CC1 PNIHOTDSIJXUMR-UHFFFAOYSA-N 0.000 description 1
ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
RFNSXSSACWHHMN-UHFFFAOYSA-N 4-benzyl-1,2-dihydrotriazol-5-one Chemical compound N1N=NC(CC=2C=CC=CC=2)=C1O RFNSXSSACWHHMN-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
208000000104 Arthus reaction Diseases 0.000 description 1
102100031491 Arylsulfatase B Human genes 0.000 description 1
241000244186 Ascaris Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
206010006448 Bronchiolitis Diseases 0.000 description 1
201000004813 Bronchopneumonia Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
FFSHBLUAJXCCMQ-UHFFFAOYSA-N C(N)(OC(C)(C)C)=O.NC1=CC=C(C=C1)CN=C=O Chemical compound C(N)(OC(C)(C)C)=O.NC1=CC=C(C=C1)CN=C=O FFSHBLUAJXCCMQ-UHFFFAOYSA-N 0.000 description 1
BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
RBOISTRYUTZGDO-JUAUBFSOSA-N Cl.NCC[C@@H]1CC[C@H](CC1)CO Chemical compound Cl.NCC[C@@H]1CC[C@H](CC1)CO RBOISTRYUTZGDO-JUAUBFSOSA-N 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
108010088842 Fibrinolysin Proteins 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
102000002261 High-Molecular-Weight Kininogen Human genes 0.000 description 1
108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
206010023203 Joint destruction Diseases 0.000 description 1
102000002397 Kinins Human genes 0.000 description 1
108010093008 Kinins Proteins 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 1
PYSJQFJJCXXCCN-UHFFFAOYSA-N N-[[4-(diaminomethylideneamino)phenyl]methyl]-3-[12-[4-[[4-(diaminomethylideneamino)phenyl]methylcarbamoyl]-1-formylpiperazin-2-yl]dodecyl]-4-formylpiperazine-1-carboxamide Chemical compound C(CCCCCCCCCCC1N(CCN(C1)C(NCC1=CC=C(C=C1)NC(=N)N)=O)C=O)CC1N(CCN(C1)C(NCC1=CC=C(C=C1)NC(=N)N)=O)C=O PYSJQFJJCXXCCN-UHFFFAOYSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
VAESJJKGQBOPNO-UHFFFAOYSA-N NC(=N)Nc1ccc(CNC(=O)C2CNCCN2C(=O)OC2CCCCCCC2)cc1 Chemical compound NC(=N)Nc1ccc(CNC(=O)C2CNCCN2C(=O)OC2CCCCCCC2)cc1 VAESJJKGQBOPNO-UHFFFAOYSA-N 0.000 description 1
QNOJCNMJPUYJGK-UHFFFAOYSA-N NC(=O)OOOC(N)=O Chemical group NC(=O)OOOC(N)=O QNOJCNMJPUYJGK-UHFFFAOYSA-N 0.000 description 1
GDIHDSKOVXEJQQ-UHFFFAOYSA-N NC(O)=O.NC(O)=O.NC(O)=O.N Chemical group NC(O)=O.NC(O)=O.NC(O)=O.N GDIHDSKOVXEJQQ-UHFFFAOYSA-N 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
CIQHWLTYGMYQQR-QMMMGPOBSA-N O(4')-sulfo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OS(O)(=O)=O)C=C1 CIQHWLTYGMYQQR-QMMMGPOBSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
241000220304 Prunus dulcis Species 0.000 description 1
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
208000036284 Rhinitis seasonal Diseases 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
102100030416 Stromelysin-1 Human genes 0.000 description 1
101710108790 Stromelysin-1 Proteins 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
102220482963 UHRF1-binding protein 1_H54N_mutation Human genes 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
YIMQCDZDWXUDCA-UHFFFAOYSA-N [4-(hydroxymethyl)cyclohexyl]methanol Chemical compound OCC1CCC(CO)CC1 YIMQCDZDWXUDCA-UHFFFAOYSA-N 0.000 description 1
HAJABMGNYPPULO-UHFFFAOYSA-N acetic acid;isocyanic acid Chemical compound N=C=O.CC(O)=O HAJABMGNYPPULO-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000013572 airborne allergen Substances 0.000 description 1
230000008371 airway function Effects 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
229940008201 allegra Drugs 0.000 description 1
201000010435 allergic urticaria Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
125000000320 amidine group Chemical group 0.000 description 1
UCOHKZKRNWNULS-UHFFFAOYSA-N aminocyanamide Chemical compound NNC#N UCOHKZKRNWNULS-UHFFFAOYSA-N 0.000 description 1
QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
150000005840 aryl radicals Chemical class 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
NHOWLEZFTHYCTP-UHFFFAOYSA-N benzylhydrazine Chemical compound NNCC1=CC=CC=C1 NHOWLEZFTHYCTP-UHFFFAOYSA-N 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910000085 borane Inorganic materials 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
230000036427 bronchial hyperreactivity Effects 0.000 description 1
230000003182 bronchodilatating effect Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
230000003523 bronchorelaxing effect Effects 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
239000004202 carbamide Chemical group 0.000 description 1
NZXRFGHWGPEIEZ-UHFFFAOYSA-N carbamimidoylazanium;2,2,2-trifluoroacetate Chemical compound NC(N)=N.OC(=O)C(F)(F)F NZXRFGHWGPEIEZ-UHFFFAOYSA-N 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001723 carbon free-radicals Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
201000009151 chronic rhinitis Diseases 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
229940125878 compound 36 Drugs 0.000 description 1
229940126540 compound 41 Drugs 0.000 description 1
229940125936 compound 42 Drugs 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
239000013058 crude material Substances 0.000 description 1
239000012045 crude solution Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000000000 cycloalkoxy group Chemical group 0.000 description 1
125000002993 cycloalkylene group Chemical group 0.000 description 1
125000005366 cycloalkylthio group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004976 cyclobutylene group Chemical group 0.000 description 1
125000005725 cyclohexenylene group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000004980 cyclopropylene group Chemical group 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000005786 degenerative changes Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
230000008378 epithelial damage Effects 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
238000003304 gavage Methods 0.000 description 1
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000005027 hydroxyaryl group Chemical group 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003999 initiator Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
DUDXQIXWPJMPRQ-UHFFFAOYSA-N isocyanatomethylcyclohexane Chemical compound O=C=NCC1CCCCC1 DUDXQIXWPJMPRQ-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000008720 membrane thickening Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
229960002329 methacholine Drugs 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 1
AAVXGCACTGMYOR-UHFFFAOYSA-N piperazine-1-carboxylic acid dihydrochloride Chemical compound Cl.Cl.OC(=O)N1CCNCC1.OC(=O)N1CCNCC1 AAVXGCACTGMYOR-UHFFFAOYSA-N 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108010029690 procollagenase Proteins 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
108010052605 prostromelysin Proteins 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000005180 public health Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
230000029547 smooth muscle hypertrophy Effects 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000005717 substituted cycloalkylene group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
WYZVDVYPSLYXPJ-UHFFFAOYSA-N tert-butyl 2-amino-6-isocyanatohexanoate Chemical compound C(C)(C)(C)OC(=O)C(CCCCN=C=O)N WYZVDVYPSLYXPJ-UHFFFAOYSA-N 0.000 description 1
ZLFWFGYLUIIJKL-UHFFFAOYSA-N tert-butyl 4-[[4-(diaminomethylideneamino)phenyl]methylcarbamoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)NCC1=CC=C(NC(N)=N)C=C1 ZLFWFGYLUIIJKL-UHFFFAOYSA-N 0.000 description 1
UXWQXBSQQHAGMG-UHFFFAOYSA-N tert-butyl n-[(4-aminophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(N)C=C1 UXWQXBSQQHAGMG-UHFFFAOYSA-N 0.000 description 1
UULGYZXPISSQLH-UHFFFAOYSA-N tert-butyl n-[(4-aminophenyl)methyl]carbamate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)NCC1=CC=C(N)C=C1 UULGYZXPISSQLH-UHFFFAOYSA-N 0.000 description 1
URXUHALBOWYXJZ-UHFFFAOYSA-N tert-butyl n-[4-(aminomethyl)phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(CN)C=C1 URXUHALBOWYXJZ-UHFFFAOYSA-N 0.000 description 1
TVCPDBXVVJKOAM-UHFFFAOYSA-N tert-butyl n-[isocyanato(phenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(N=C=O)C1=CC=CC=C1 TVCPDBXVVJKOAM-UHFFFAOYSA-N 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960001322 trypsin Drugs 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

SK379-97A 1994-09-23 1995-09-14 Compositions and methods for treating mast-cell inflammatory condition SK37997A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31226994A	1994-09-23	1994-09-23
PCT/US1995/011814 WO1996009297A1 (en)	1994-09-23	1995-09-14	Compositions and methods for treating mast-cell inflammatory condition

Publications (1)

Publication Number	Publication Date
SK37997A3 true SK37997A3 (en)	1998-12-02

Family

ID=23210670

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK379-97A SK37997A3 (en)	1994-09-23	1995-09-14	Compositions and methods for treating mast-cell inflammatory condition

Country Status (25)

Country	Link
US (2)	US6022969A (cs)
EP (1)	EP0782571A1 (cs)
JP (1)	JPH10506390A (cs)
KR (1)	KR970706267A (cs)
CN (1)	CN1160398A (cs)
AU (1)	AU694275B2 (cs)
CA (1)	CA2200561A1 (cs)
CZ (1)	CZ87097A3 (cs)
EE (1)	EE03525B1 (cs)
FI (1)	FI971171A7 (cs)
HR (1)	HRP950499B1 (cs)
HU (1)	HUT77770A (cs)
IL (1)	IL115405A (cs)
LT (1)	LT4234B (cs)
LV (1)	LV11865B (cs)
MX (1)	MX9702125A (cs)
NO (1)	NO309605B1 (cs)
NZ (1)	NZ294392A (cs)
PL (1)	PL183552B1 (cs)
RU (1)	RU2159229C2 (cs)
SI (1)	SI9520101A (cs)
SK (1)	SK37997A3 (cs)
TW (1)	TW442478B (cs)
WO (1)	WO1996009297A1 (cs)
ZA (1)	ZA958028B (cs)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EE9900036A (et) *	1996-07-30	1999-08-16	Arris Pharmaceutical Corporation	Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
WO1998024886A1 (en) *	1996-12-04	1998-06-11	Brigham And Women's Hospital, Inc.	Mast cell protease that cleaves fibrinogen
US5955431A (en) *	1997-02-05	1999-09-21	Brigham And Women's Hospital, Inc.	Mast cell protease peptide inhibitors
WO1999012918A1 (en) *	1997-09-05	1999-03-18	Yoshitomi Pharmaceutical Industries, Ltd.	Tryptase inhibitor
AU1208999A (en) *	1997-11-10	1999-05-31	Array Biopharma, Inc.	Compounds which inhibit tryptase activity
US6221914B1 (en) *	1997-11-10	2001-04-24	Array Biopharma Inc.	Sulfonamide bridging compounds that inhibit tryptase activity
EP1060171A2 (de)	1998-02-06	2000-12-20	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Tryptase-inhibitoren
US6489327B1 (en)	1998-02-06	2002-12-03	Max-Planck-Gesellschaft Zur Fordrungder Wisenschaften, E.V.	Tryptase inhibitors
EP1115731A2 (de) *	1998-09-04	2001-07-18	Byk Gulden Lomberg Chemische Fabrik GmbH	Neue pyranosen
US6362216B1 (en)	1998-10-27	2002-03-26	Array Biopharma Inc.	Compounds which inhibit tryptase activity
US6849605B1 (en) *	1999-03-05	2005-02-01	The Trustees Of University Technology Corporation	Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3731400A (en) *	1999-03-05	2000-09-21	Trustees Of University Technology Corporation, The	Methods and compositions useful in inhibiting apoptosis
KR20020016942A (ko) *	1999-08-10	2002-03-06	빅 굴덴 롬베르크 케미쉐 파브릭 게엠베하	디아조신-디온 유도체 및 이것의 트립타제 억제제로서 용도
DE19940389A1 (de) *	1999-08-25	2001-03-01	Wilex Biotechnology Gmbh	Selektive Inhibitoren des Urokinase-Plasminogen Aktivators
AU778965B2 (en) *	1999-09-14	2004-12-23	Altana Pharma Ag	Tryptase inhibitors
GB9923710D0 (en) *	1999-10-08	1999-12-08	Proteus Molecular Design	Chemical compounds
WO2001036386A1 (en) *	1999-11-17	2001-05-25	Sumitomo Pharmaceuticals Co., Ltd.	Diabetic remedy containing dipiperazine derivative
CA2392127A1 (en) *	1999-12-20	2001-06-28	Byk Gulden Lomberg Chemische Fabrik Gmbh	Tryptase inhibitors
AU783217B2 (en) *	1999-12-20	2005-10-06	Altana Pharma Ag	Tryptase inhibitors
AU2001231030A1 (en) *	2000-01-20	2001-07-31	Amgen Inc	Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
US20020045613A1 (en) *	2000-04-27	2002-04-18	Heinz Pauls	1-aroyl-piperidinyl benzamidines
ES2225758T3 (es)	2001-01-31	2005-03-16	Altana Pharma Ag	Derivdos de diazocina y su uso como agentes inhibidores de la triptasa.
EP1368317B1 (en)	2001-02-21	2006-12-27	Altana Pharma AG	Tryptase inhibitors
JP2004518735A (ja) *	2001-02-21	2004-06-24	アルタナ　ファルマ　アクチエンゲゼルシャフト	トリプターゼインヒビター
AU2002254941B2 (en) *	2001-03-15	2007-05-17	Altana Pharma Ag	Tryptase-inhibitors
WO2002074732A2 (en) *	2001-03-15	2002-09-26	Altana Pharma Ag	Tryptase-inhibitors
US6818787B2 (en) *	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en)	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) *	2001-06-11	2007-06-19	Xenoport, Inc.	Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
CA2450659A1 (en)	2001-06-19	2002-12-27	Altana Pharma Ag	Tryptase inhibitors
EP1455765A2 (en) *	2001-12-13	2004-09-15	Kowa Company Ltd.	Use of protease-activated receptor-2 inhibitor in the manufacture of a medicament for treating delayed hypersensitivity
WO2003075853A2 (en)	2002-03-08	2003-09-18	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
TW200524849A (en) *	2003-07-02	2005-08-01	Hoffmann La Roche	Hydroxyalkylamide derivatives
RU2276973C2 (ru) *	2004-01-22	2006-05-27	Общество с ограниченной ответственностью "Лечебно-диагностическая фирма "Медик"	Противовоспалительная мазь с гиполипидемическим эффектом
US20050255154A1 (en) *	2004-05-11	2005-11-17	Lena Pereswetoff-Morath	Method and composition for treating rhinitis
TW200815351A (en) *	2006-05-02	2008-04-01	Astrazeneca Ab	Novel compounds
TWI414527B (zh) *	2010-10-06	2013-11-11	Ind Tech Res Inst	異山梨糖醇衍生物及包含該衍生物之液晶顯示器
CN102453037B (zh) *	2010-10-25	2014-06-25	财团法人工业技术研究院	异山梨糖醇衍生物及包含该衍生物的液晶显示器

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR208414A1 (es) *	1974-11-07	1976-12-27	Rhone Poulenc Ind	Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4746737A (en) *	1985-07-26	1988-05-24	Kowa Co., Ltd.	Phenyl guanidinobenzoate derivatives which have protease inhibitory activity
AU683459B2 (en) *	1993-03-12	1997-11-13	Arris Pharmaceutical Corporation	Compositions and methods for the treatment of immunomediated inflammatory disorders
US5525623A (en) *	1993-03-12	1996-06-11	Arris Pharmaceutical Corporation	Compositions and methods for the treatment of immunomediated inflammatory disorders
AU2764495A (en) *	1994-06-01	1995-12-21	Arris Pharmaceutical Corporation	Compositions and methods for treating mast-cell mediated conditions

1995
- 1995-09-14 PL PL95319587A patent/PL183552B1/pl unknown
- 1995-09-14 KR KR1019970701960A patent/KR970706267A/ko not_active Ceased
- 1995-09-14 NZ NZ294392A patent/NZ294392A/xx unknown
- 1995-09-14 US US08/522,157 patent/US6022969A/en not_active Expired - Fee Related
- 1995-09-14 WO PCT/US1995/011814 patent/WO1996009297A1/en not_active Ceased
- 1995-09-14 CZ CZ97870A patent/CZ87097A3/cs unknown
- 1995-09-14 RU RU97106347/04A patent/RU2159229C2/ru not_active IP Right Cessation
- 1995-09-14 CA CA002200561A patent/CA2200561A1/en not_active Abandoned
- 1995-09-14 AU AU37180/95A patent/AU694275B2/en not_active Ceased
- 1995-09-14 FI FI971171A patent/FI971171A7/fi unknown
- 1995-09-14 CN CN95195191A patent/CN1160398A/zh active Pending
- 1995-09-14 SI SI9520101A patent/SI9520101A/sl unknown
- 1995-09-14 HU HU9702059A patent/HUT77770A/hu unknown
- 1995-09-14 MX MX9702125A patent/MX9702125A/es not_active IP Right Cessation
- 1995-09-14 SK SK379-97A patent/SK37997A3/sk unknown
- 1995-09-14 EE EE9700089A patent/EE03525B1/xx not_active IP Right Cessation
- 1995-09-14 JP JP8511002A patent/JPH10506390A/ja not_active Ceased
- 1995-09-14 EP EP95934993A patent/EP0782571A1/en not_active Withdrawn
- 1995-09-22 IL IL11540595A patent/IL115405A/en not_active IP Right Cessation
- 1995-09-22 ZA ZA958028A patent/ZA958028B/xx unknown
- 1995-09-22 HR HR950499A patent/HRP950499B1/xx not_active IP Right Cessation
- 1995-09-26 TW TW084110031A patent/TW442478B/zh active
1997
- 1997-03-20 NO NO971305A patent/NO309605B1/no unknown
- 1997-04-10 LT LT97-065A patent/LT4234B/lt not_active IP Right Cessation
- 1997-04-22 LV LVP-97-70A patent/LV11865B/en unknown
1999
- 1999-03-29 US US09/280,227 patent/US6211228B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
FI971171A0 (fi)	1997-03-20
CZ87097A3 (en)	1997-11-12
CA2200561A1 (en)	1996-03-28
SI9520101A (en)	1997-12-31
IL115405A0 (en)	1995-12-31
EP0782571A1 (en)	1997-07-09
RU2159229C2 (ru)	2000-11-20
NO309605B1 (no)	2001-02-26
HUT77770A (hu)	1998-08-28
MX9702125A (es)	1998-04-30
LT4234B (en)	1997-10-27
FI971171L (fi)	1997-03-20
HRP950499B1 (en)	2003-04-30
ZA958028B (en)	1996-04-18
LT97065A (en)	1997-08-25
AU3718095A (en)	1996-04-09
IL115405A (en)	2002-07-25
JPH10506390A (ja)	1998-06-23
TW442478B (en)	2001-06-23
WO1996009297A1 (en)	1996-03-28
FI971171A7 (fi)	1997-03-20
HRP950499A2 (en)	1997-08-31
CN1160398A (zh)	1997-09-24
US6022969A (en)	2000-02-08
LV11865B (en)	1998-01-20
EE03525B1 (et)	2001-10-15
AU694275B2 (en)	1998-07-16
NZ294392A (en)	1999-05-28
EE9700089A (et)	1997-10-15
US6211228B1 (en)	2001-04-03
NO971305L (no)	1997-05-06
LV11865A (lv)	1997-10-20
PL183552B1 (pl)	2002-06-28
NO971305D0 (no)	1997-03-20
PL319587A1 (en)	1997-08-18
KR970706267A (ko)	1997-11-03

Publication	Publication Date	Title
SK37997A3 (en)	1998-12-02	Compositions and methods for treating mast-cell inflammatory condition
US5656660A (en)	1997-08-12	Compositions and methods for treating mast-cell mediated conditions
SK8599A3 (en)	2000-03-13	Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal
JP2002502850A (ja)	2002-01-29	トリプターゼ阻害物質
ES2222259T3 (es)	2005-02-01	Inhibidores de triptasa.
MXPA02001426A (es)	2002-08-12	Derivados de diazocin-diona y su uso como inhibidores de triptasa.
ES2222270T3 (es)	2005-02-01	Inhibidores de triptasa.
EP1401809B1 (en)	2006-12-20	Tryptase inhibitors
EP1368317B1 (en)	2006-12-27	Tryptase inhibitors
JP2004525926A (ja)	2004-08-26	トリプターゼ阻害剤